成人B细胞急性淋巴细胞白血病患者在接受CD19 CAR T细胞治疗后达到微小残留病阴性完全缓解并获得持久无事件生存的相关因素
本研究在一项1/2期临床试验中,对53例接受CD19 CAR T细胞治疗的复发/难治B-ALL患者进行分析,45例(85%)达到微小残留病阴性完全缓解。中位随访30.9个月,达到微小残留病阴性完全缓解的患者无事件生存期和总生存期显著优于未达到者。在多因素分析中,较低的淋巴细胞清除前乳酸脱氢酶浓度、较高的淋巴细胞清除前血小板计数、淋巴细胞清除方案中包含氟达拉滨以及CAR T细胞治疗后接受异基因造血干细胞移植与更好的无事件生存期相关。
要点
- 53例可评估患者中45例(85%)达到微小残留病阴性完全缓解。
- 中位随访30.9个月,达到微小残留病阴性完全缓解者中位无事件生存期7.6个月 vs 未达到者0.8个月(P < .0001)。
- 在多因素分析中,较低的淋巴细胞清除前乳酸脱氢酶、较高的淋巴细胞清除前血小板计数、包含氟达拉滨的淋巴细胞清除方案及后续异基因造血干细胞移植与更好的无事件生存期相关。
核心结论
- 在达到微小残留病阴性完全缓解的患者中,通过IGH深度测序确认索引恶性克隆消失与更好的无事件生存期相关(P = .034)。
- 多因素分析显示较低的淋巴细胞清除前乳酸脱氢酶浓度(每增加100 U/L,风险比[HR] 1.38)、较高的淋巴细胞清除前血小板计数(每增加50 000/μL,HR 0.74)、淋巴细胞清除方案中包含氟达拉滨(HR 0.25)以及CAR T细胞治疗后接受异基因造血干细胞移植(HR 0.39)与更好的无事件生存期相关。
- 这些数据有助于识别CAR T细胞免疫治疗后复发风险较高、可能从异基因造血干细胞移植等巩固策略中获益的患者。
研究设计与样本
- 研究为在单一机构开展的1/2期临床试验(注册号NCT01865617),纳入复发/难治B细胞急性淋巴细胞白血病患者,接受淋巴细胞清除化疗后CD19 CAR T细胞治疗。
- 共有53例患者接受CD19 CAR T细胞治疗并可评估疗效,其中45例(85%)通过高分辨率流式细胞术达到微小残留病阴性完全缓解。
主要发现
- 中位随访30.9个月,达到微小残留病阴性完全缓解的患者中位无事件生存期为7.6个月 vs 未达到者0.8个月(P < .0001)。
- 达到微小残留病阴性完全缓解的患者中位总生存期为20.0个月 vs 未达到者5.0个月(P = .014)。
- 在通过流式细胞术达到微小残留病阴性完全缓解的患者中,通过IGH深度测序确认索引恶性克隆消失与更好的无事件生存期相关(P = .034)。
关键数值与推荐
- 多因素分析中,淋巴细胞清除前乳酸脱氢酶浓度每增加100 U/L,风险比[HR]为1.38。
- 淋巴细胞清除前血小板计数每增加50 000/μL,风险比[HR]为0.74。
- 淋巴细胞清除方案中包含氟达拉滨的风险比[HR]为0.25。
- CAR T细胞治疗后接受异基因造血干细胞移植的风险比[HR]为0.39。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR) have produced impressive minimal residual disease-negative (MRD-negative) complete remission (CR) rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the factors associated with durable remissions after CAR T-cell therapy have not been fully elucidated. We studied patients with relapsed/refractory B-ALL enrolled in a phase 1/2 clinical trial evaluating lymphodepletion chemotherapy followed by CD19 CAR T-cell therapy at our institution. Forty-five (85%) of 53 patients who received CD19 CAR T-cell therapy and were evaluable for response achieved MRD-negative CR by high-resolution flow cytometry. With a median follow-up of 30.9 months, event-free survival (EFS) and overall survival (OS) were significantly better in the patients who achieved MRD-negative CR compared with those who did not (median EFS, 7.6 vs 0.8 months; P < .0001; median OS, 20.0 vs 5.0 months; P = .014). In patients who achieved MRD-negative CR by flow cytometry, absence of the index malignant clone by IGH deep sequencing was associated with better EFS (P = .034). Stepwise multivariable modeling in patients achieving MRD-negative CR showed that lower prelymphodepletion lactate dehydrogenase concentration (hazard ratio [HR], 1.38 per 100 U/L increment increase), higher prelymphodepletion platelet count (HR, 0.74 per 50 000/μL increment increase), incorporation of fludarabine into the lymphodepletion regimen (HR, 0.25), and allogeneic hematopoietic cell transplantation (HCT) after CAR T-cell therapy (HR, 0.39) were associated with better EFS. These data allow identification of patients at higher risk of relapse after CAR T-cell immunotherapy who might benefit from consolidation strategies such as allogeneic HCT. This trial was registered at www.clinicaltrials.gov as #NCT01865617.
引用
- Hay KA, Gauthier J, Hirayama AV, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019. PMID: 30728140. doi:10.1182/blood-2018-11-883710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。